Provision of gastroprotective medication and bleeding risk following acute coronary syndrome

Journal of Invasive Cardiology

Volumn 25, Issue 8, 2013, Pages 397-401

  Badar, Athar ^a,b   Scaife, Jennifer ^a   Yan, Andrew T ^c   Robinson, Simon D ^d   Zaman, Azfar G ^a,e   Purcell, Ian F ^a   Ahmed, Javed M ^a   Egred, Mohaned ^a,e   Edwards, Richard J ^a   Spyridopoulos, Ioakim ^a,f   Keavney, Bernard D ^f,g   Bagnall, Alan J ^a,e  

^a FREEMAN HOSPITAL   (United Kingdom)

^b FORTH VALLEY ROYAL HOSPITAL   (United Kingdom)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ROYAL JUBILEE HOSPITAL   (Canada)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

acute coronary syndrome; bleeding; delivery of care; risk stratification

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR RISK; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN; RETROSPECTIVE STUDY; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84882423616     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4(2):191-197.
2. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200-1206.
3. Nikolsky E, Mehran R, Sadeghi HM, et al. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. JACC Cardiovasc Interv. 2009;2(7):624-632.
4. Abbas AE, Brodie B, Dixon S, et al. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005;96(2):173-176.
5. Chin MW, Yong G, Bulsara MK, et al. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol. 2007;102(11):2411-2416.
6. Alli O, Smith C, Hoffman M, et al. Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Clin Gastroenterol. 2011;45(5):410-414.
7. Shivaraju A, Patel V, Fonarow GC, et al. Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. Am Heart J. 2011;162(6):1062-1068.e5.
8. Gaglia MA Jr, Torguson R, Gonzalez MA, et al. Correlates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention. Am J Cardiol. 2010;106(8):1069-1074.
9. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917.
10. Ng FH, Wong SY, Lam KF, et al. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol. 2008;103(4):865-871.
11. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502-1517.
12. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574-e651.
13. Medicines and Healthcare Products Regulatory Agency website. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087962. Accessed Dec, 2012.
14. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28(16):1936-1945.
15. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24(20):1815-1823.
16. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930-935.
17. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;56(24):2051-2066.
18. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509.
19. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256-260.
20. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170(8):704-710.
21. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944.
22. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997.
23. Medicines and Healthcare Products Regulatory Agency website. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087711#ref2. Accessed Dec, 2012.
24. Bagnall AJ, Goodman SG, Fox KA, et al. Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST elevation acute coronary syndromes. Am J Cardiol. 2009;103(11):1530-1536.
25. Bagnall AJ, Yan AT, Yan RT, et al. Optimal medical therapy for non-ST segment elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes. 2010;3(5):530-537.
26. Fox KA, Anderson FA Jr, Dabbous OH, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart. 2007;93(2):177-182.
27. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556-2566.
28. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119(14):1873-1882.
29. Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34,701 arthritis patients. Aliment Pharmacol Ther. 2010;32(10):1240-1248.